The role of innovative genetic testing as a companion to medical treatment is often linked to the prediction of how effective a certain treatment will be. However, such tests can also determine whether giving a patient a drug could result in a life-altering reaction, as is the case with commonly prescribed antibiotic gentamicin.
In new draft guidance issued as part of a medtech reimbursement pilot scheme, the UK’s National Institute of health and Care Excellence (NICE) recommended the funding of the genedrive...
EVA Timeline
In August 2022, NICE made its first EVA draft decision. AliveCor’s KardiaMobile 6L, a portable ECG that wirelessly records and transmits data,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?